JP2008535841A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008535841A5 JP2008535841A5 JP2008505489A JP2008505489A JP2008535841A5 JP 2008535841 A5 JP2008535841 A5 JP 2008535841A5 JP 2008505489 A JP2008505489 A JP 2008505489A JP 2008505489 A JP2008505489 A JP 2008505489A JP 2008535841 A5 JP2008535841 A5 JP 2008535841A5
- Authority
- JP
- Japan
- Prior art keywords
- ctla4 mutant
- use according
- mutant molecule
- regimen
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66877405P | 2005-04-06 | 2005-04-06 | |
| PCT/US2006/012648 WO2006108035A1 (en) | 2005-04-06 | 2006-04-05 | Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008535841A JP2008535841A (ja) | 2008-09-04 |
| JP2008535841A5 true JP2008535841A5 (https=) | 2009-05-21 |
Family
ID=36694299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008505489A Pending JP2008535841A (ja) | 2005-04-06 | 2006-04-05 | 可溶性ｃｔｌａ４変異分子によるグラフト移植に関連する免疫不全の治療方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7482327B2 (https=) |
| EP (1) | EP1868635B1 (https=) |
| JP (1) | JP2008535841A (https=) |
| KR (1) | KR101235484B1 (https=) |
| CN (1) | CN101198347A (https=) |
| AR (1) | AR055052A1 (https=) |
| AU (1) | AU2006231622B2 (https=) |
| BR (1) | BRPI0608144A2 (https=) |
| CA (1) | CA2603970A1 (https=) |
| CY (1) | CY1119145T1 (https=) |
| DK (1) | DK1868635T3 (https=) |
| EA (1) | EA013122B1 (https=) |
| ES (1) | ES2634260T3 (https=) |
| HR (1) | HRP20171121T8 (https=) |
| IL (1) | IL186189A (https=) |
| LT (1) | LT1868635T (https=) |
| ME (1) | ME02930B (https=) |
| MX (1) | MX2007012222A (https=) |
| NO (1) | NO342966B1 (https=) |
| NZ (2) | NZ561655A (https=) |
| PL (1) | PL1868635T3 (https=) |
| PT (1) | PT1868635T (https=) |
| RS (1) | RS56138B1 (https=) |
| SI (1) | SI1868635T1 (https=) |
| WO (1) | WO2006108035A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| BRPI0608144A2 (pt) * | 2005-04-06 | 2009-11-17 | Bristol Myers Squibb Co | uso de uma molécula mutante de ctla4 |
| US9309316B2 (en) | 2005-12-20 | 2016-04-12 | Bristol-Myers Squibb Company | Stable subcutaneous protein formulations and uses thereof |
| US7528111B2 (en) * | 2006-05-12 | 2009-05-05 | Bristol-Myers Squibb Company | Method of vaccinating subjects receiving immune modulating therapy |
| WO2008014035A2 (en) * | 2006-07-25 | 2008-01-31 | The Regents Of The University Of California | Modulation of nkg2d and method for treating or preventing solid organ allograft rejection |
| AU2008319053B2 (en) | 2007-11-01 | 2012-04-26 | Astellas Pharma Inc. | Immunosuppressive polypeptides and nucleic acids |
| WO2010098788A2 (en) * | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| EP2365823B1 (en) * | 2008-10-30 | 2016-11-30 | Yeda Research And Development Company Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
| WO2010132891A1 (en) * | 2009-05-15 | 2010-11-18 | The Board Of Trustees Of The Leland Stanford Junior University | Combination therapy to inhibit t cell effector function |
| PL3053932T3 (pl) * | 2010-02-19 | 2021-03-08 | Xencor, Inc. | Nowe immunoadhezyny CTLA4-IG |
| CN106432474A (zh) | 2010-03-12 | 2017-02-22 | 艾伯维生物医疗股份有限公司 | Ctla4蛋白和其用途 |
| MX357746B (es) | 2010-09-08 | 2018-07-23 | Yeda Res And Development Co Ltd Star | Uso de células t de memoria central anti-tercera parte para el tratamiento anti-leucemia/linfoma. |
| KR20130105652A (ko) | 2010-09-08 | 2013-09-25 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 안정하고 장기간의 인그래프트먼트를 위한 면역억제 약물의 조합 |
| AU2012305931B2 (en) | 2011-09-08 | 2017-09-07 | Yeda Research And Development Co. Ltd | Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment |
| SMT202000091T1 (it) | 2011-10-13 | 2020-05-08 | Bristol Myers Squibb Co | Polipeptidi anticorpali che antagonizzano cd40l |
| BR112015024516A2 (pt) * | 2013-03-28 | 2017-10-24 | Bristol Myers Squibb Co | métodos para identificar pacientes em risco de rejeição resistente ao bloqueio de coestimulação |
| CN104673822A (zh) * | 2013-11-27 | 2015-06-03 | 深圳先进技术研究院 | 一种重组载体及其制备方法和应用 |
| CN104740608A (zh) * | 2013-12-30 | 2015-07-01 | 上海中信国健药业股份有限公司 | 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途 |
| EA201691634A1 (ru) | 2014-03-19 | 2016-11-30 | Бристол-Маерс Сквибб Компани | Способы лечения отторжения трансплантата с использованием доменного антитела, направленного против cd40l |
| MA41459A (fr) * | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| EP3283508B1 (en) | 2015-04-17 | 2021-03-17 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| JP7057748B2 (ja) | 2015-07-16 | 2022-04-20 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッド | 遺伝子改変された抗第三者中枢性メモリーｔ細胞および免疫療法におけるその使用 |
| US10751368B2 (en) | 2017-01-18 | 2020-08-25 | Yeda Research And Development Co. Ltd. | Methods of transplantation and disease treatment |
| CN110392736A (zh) | 2017-01-18 | 2019-10-29 | 耶达研究及发展有限公司 | 遗传修饰的反抑细胞及其在免疫治疗中的用途 |
| US10286036B2 (en) | 2017-05-12 | 2019-05-14 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| KR102813968B1 (ko) | 2017-10-10 | 2025-05-29 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
| SG11202006148UA (en) | 2018-01-03 | 2020-07-29 | Alpine Immune Sciences Inc | Multi-domain immunomodulatory proteins and methods of use thereof |
| EP3809983B1 (en) | 2018-06-22 | 2025-08-27 | Mayo Foundation for Medical Education and Research | Methods and materials for improving arteriovenous fistula maturation and maintaining arteriovenous fistula functionality |
| WO2020010259A1 (en) * | 2018-07-06 | 2020-01-09 | Mayo Foundation For Medical Education And Research | Methods and materials for improving transplant outcomes |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| CN115089718B (zh) * | 2021-11-30 | 2024-05-28 | 杭州瑞普晨创科技有限公司 | 用于异种移植的免疫抑制剂组合和免疫抑制方法 |
| KR102929448B1 (ko) | 2023-02-03 | 2026-02-26 | 이뮤노바이옴 주식회사 | 이식 거부 반응의 예방 또는 치료용 조성물 |
| WO2024211211A1 (en) | 2023-04-03 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| DE69226871T3 (de) | 1991-06-27 | 2009-09-24 | Bristol-Myers Squibb Co. | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| US6090914A (en) | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US5773253A (en) | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| AU2002243905B2 (en) * | 2001-01-26 | 2007-11-08 | Emory University | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| MXPA03010568A (es) * | 2001-05-23 | 2005-03-07 | Squibb Bristol Myers Co | Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles. |
| WO2003088991A1 (en) * | 2002-04-19 | 2003-10-30 | Bristol-Myers Squibb Company | Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid |
| CN101857851A (zh) | 2002-12-23 | 2010-10-13 | 布里斯托尔-迈尔斯斯奎布公司 | 用于蛋白质生产的哺乳动物细胞培养方法 |
| DE60335024D1 (de) | 2002-12-23 | 2010-12-30 | Bristol Myers Squibb Co | Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| BRPI0608144A2 (pt) * | 2005-04-06 | 2009-11-17 | Bristol Myers Squibb Co | uso de uma molécula mutante de ctla4 |
-
2006
- 2006-04-05 BR BRPI0608144-4A patent/BRPI0608144A2/pt not_active Application Discontinuation
- 2006-04-05 CA CA002603970A patent/CA2603970A1/en not_active Abandoned
- 2006-04-05 WO PCT/US2006/012648 patent/WO2006108035A1/en not_active Ceased
- 2006-04-05 ME MEP-2017-162A patent/ME02930B/me unknown
- 2006-04-05 NZ NZ561655A patent/NZ561655A/en not_active IP Right Cessation
- 2006-04-05 DK DK06749324.7T patent/DK1868635T3/en active
- 2006-04-05 PL PL06749324T patent/PL1868635T3/pl unknown
- 2006-04-05 CN CNA2006800198976A patent/CN101198347A/zh active Pending
- 2006-04-05 SI SI200632175A patent/SI1868635T1/sl unknown
- 2006-04-05 MX MX2007012222A patent/MX2007012222A/es active IP Right Grant
- 2006-04-05 HR HRP20171121TT patent/HRP20171121T8/hr unknown
- 2006-04-05 ES ES06749324.7T patent/ES2634260T3/es not_active Expired - Lifetime
- 2006-04-05 KR KR1020077025644A patent/KR101235484B1/ko not_active Expired - Lifetime
- 2006-04-05 EP EP06749324.7A patent/EP1868635B1/en not_active Expired - Lifetime
- 2006-04-05 EA EA200702180A patent/EA013122B1/ru active IP Right Revival
- 2006-04-05 LT LTEP06749324.7T patent/LT1868635T/lt unknown
- 2006-04-05 JP JP2008505489A patent/JP2008535841A/ja active Pending
- 2006-04-05 PT PT67493247T patent/PT1868635T/pt unknown
- 2006-04-05 RS RS20170794A patent/RS56138B1/sr unknown
- 2006-04-05 AU AU2006231622A patent/AU2006231622B2/en not_active Expired
- 2006-04-06 US US11/399,666 patent/US7482327B2/en not_active Expired - Lifetime
- 2006-04-06 AR ARP060101377A patent/AR055052A1/es unknown
-
2007
- 2007-09-23 IL IL186189A patent/IL186189A/en active IP Right Grant
- 2007-10-09 NO NO20075078A patent/NO342966B1/no unknown
-
2008
- 2008-11-19 US US12/313,342 patent/US20100041602A1/en not_active Abandoned
-
2009
- 2009-04-21 NZ NZ576434A patent/NZ576434A/en not_active IP Right Cessation
-
2017
- 2017-07-28 CY CY20171100812T patent/CY1119145T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008535841A5 (https=) | ||
| Post et al. | Immunosuppression in liver transplantation | |
| HRP20171121T1 (hr) | Metode za liječenje imunoloških poremećaja povezanih sa transplatacijom grafta sa solubilnim ctla4 mutiranim molekulama | |
| Barshes et al. | Pharmacologic immunosuppression | |
| JP2013543501A5 (https=) | ||
| Lo et al. | P‐glycoprotein and drug therapy in organ transplantation | |
| JP2006527193A5 (https=) | ||
| Nguyen et al. | Intravitreal sirolimus for the treatment of noninfectious uveitis: evolution through preclinical and clinical studies | |
| JP2014114288A5 (https=) | ||
| JP2013539352A5 (https=) | ||
| JP2014505056A5 (https=) | ||
| JP2015500822A5 (https=) | ||
| JP2021534165A5 (https=) | ||
| Siddique et al. | Road to remission: a comprehensive review of therapy in uveitis | |
| TW200529861A (en) | Methods and reagents for the treatment of inflammatory disorders | |
| WO2009078998A1 (en) | Therapeutic regimens for the treatment of immunoinflammatory disorders | |
| JP2007517766A (ja) | 薬物の組み合わせを投与するための治療法 | |
| Lo et al. | Strategies to reduce toxicities and improve outcomes in renal transplant recipients | |
| IL293705A (en) | Antibodies for the treatment of chronic graft-versus-host disease | |
| JP2002530354A (ja) | 移植の拒絶反応の出現の処置に使用するためのｃｄ２５結合分子 | |
| CN114423455A (zh) | 用于治疗系统性硬化症的药物组合物 | |
| JP2002530354A5 (https=) | ||
| Shivhare et al. | Role of immunomodulators in oral diseases | |
| Krieger et al. | Novel immunosuppressants | |
| CN112773802B (zh) | 一种化合物用于预防或治疗移植物抗宿主病的用途 |